No Data
BTIG Maintains Akebia Therapeutics(AKBA.US) With Buy Rating, Raises Target Price to $10
Express News | Akebia Therapeutics Inc : Btig Raises Target Price to $10 From $5
Even After Rising 18% This Past Week, Akebia Therapeutics (NASDAQ:AKBA) Shareholders Are Still Down 74% Over the Past Five Years
Akebia Therapeutics Analyst Ratings
H.C. Wainwright Maintains Akebia Therapeutics(AKBA.US) With Buy Rating, Maintains Target Price $7.5
Akebia Announced Near 100% U.S. Dialysis Coverage For Vafseo, Vafseo Shipments Commence, Phase 3 Trial For Late-Stage Non-Dialysis CKD Patients Planned for Mid-2025
103851773 : what means of possible swing bro?
Jaguar8 OP 103851773 : Swing means possible hold for January
70108039 103851773 : don't listen to anybody listen to yourself only
103851773 Jaguar8 OP : okay, thanks ya.![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined")
GG4WIN : AH mean, sorry not too gd w short form? txs for your detail analysis and i will recommend you to others for follows
View more comments...